Abstract 22P
Background
Chemotoxicity may cause sarcopenia, representing a loss of muscle strength and mass, which reduces quality of life (QoL) and physical function. Most of the breast cancer patients underwent chemotherapy reported significant aftereffects. However, the evaluation of muscle strength and QoL were still limited. Hereby, the study aims to evaluate the correlation between muscle strength and QoL in Indonesian breast cancer patients.
Methods
Participants were breast cancer women who underwent chemotherapy. Muscle strength was measured with a JAMAR handgrip. Breast cancer patients were evaluated their QoL from global health status and functional status which compromises the physical functioning (PF), role functioning (RF), emotional functioning (EF), cognitive functioning (CF) social functioning (SF). Assessment was done using the EORTC QLQ-C30. The correlation was analyzed with Pearson and Spearman correlation test.
Results
A population of 80 breast cancer women was involved, with a mean age of 47.39±7.0, median BMI of 23.15 (7.86-47.26) kg/m2 and median muscle strength of 16.5 (3-29) kg. The majority of the patients were stage 2 on diagnosis (76.3%). Median score for each domains were as followed, global health status=66.67(0-100); PF=93.33(0-133.33); RF=100(0-133.33); EF=83.33(33.33-100); CF=100(16.67-100); and SF=100(0-100). Correlations were found between muscle strength and global health status (r=0.282, p=0.011), PF (r=0.373, p=0.001), RF (r=0.26, p=0.02) whilst no correlation with EF (r=-0.68, p=0.549), CF (r=0.038, p=0.738), and SF(r=0.214, p=0.056).
Conclusions
Muscle strength was correlated with quality of life, specifically in global health status, physical functioning, and role functioning in breast cancer patients. Overall, nearly all of the domains have good outcomes. Further assessment in patients’ nutritional status and physical activity were needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session